Today, Ampcontrol has unveiled its fully developed emergency ventilator, the ‘Ventasys’, reinforcing local manufacturing capability and a highly skilled region ready for the next generation of product innovation.
A partner of the Ventilator Innovation Project between NSW Government, universities, and industry, Ampcontrol responded to the NSW Government’s ‘call-to-arms’ in March 2020 to design and develop a low-cost, life-saving back-up ventilator solution during the COVID-19 pandemic.
On hand to see the first Ventasys units complete production, Ampcontrol Managing Director & CEO, Rod Henderson said he was very optimistic for the future of the local manufacturing industry.
“To turn a concept into a first-class lifesaving piece of medical equipment within such a critical timeframe is testament to the highly advanced capability and skilled expertise in our region. The collaborative approach adopted to tackle this project in conjunction with clinicians at the John Hunter Hospital, proves the ability of the local industry to rapidly pivot and solve unique problems.
What this rapid innovation health project has brought to the forefront, and more broadly as a country over the past 6 months, is what can be quickly achieved when there are strong partnerships between government, university, and industry. We have shown that we can do these things better and more quickly in Australia.”
As a member of the Committee For The Hunter and the Hunter Central MedTech Industry Network, Ampcontrol strongly advocates for continued government partnerships to boost jobs and the economy through investment in research & development, infrastructure, and product innovation.
“With the continued support of government, I am confident as a region we can build an industry leading medical manufacturing hub where businesses, researchers, students, and trainees work side-by-side developing new ideas, learning pathways, products and services with commercial application. The development of strategically important domestic manufacturing within the Hunter will provide immense benefit to the local industry, economy, and community,” Mr. Henderson added.
With prototyping, pre-production, and clinical user group assessment and testing now completed, application for TGA (Therapeutic Goods Administration) ‘Permission To Supply’ the Ventasys for COVID-19 use in Australia is expected to be granted in the coming weeks.
The Ventasys will now progress to the manufacturing phase with components ordered for up to 100 units. Ampcontrol will also conduct further software engineering to provide the additional sophisticated ventilator functionality requested by NSW Health clinicians and integrate them into Intensive Care Unit electronic medical record systems.